ICA, Inc.’s Post

Join Dr. Pathik Amin for a complimentary webinar on the clinical utility of OCT in glaucoma detection and learn how he uses scan protocols and reports to rule out glaucoma masqueraders and confirm glaucoma diagnosis. “Glaucoma and SPECTRALIS SD-OCT: Diagnosis, Masqueraders, and Clinical Pearls,” Thursday, January 25 from 7:00 - 8:00 pm ET. Session objectives include reviewing commonly utilized scan protocols and reports for glaucoma diagnosis, recognizing ocular conditions that can mimic glaucoma, and understanding clinical utility, common pitfalls, and green/red disease. Sign up here: https://lnkd.in/ezHsAqtG #HeidelbergEngineering #HeidelbergEngineeringUS #glaucoma #SPECTRALIS #OCT #glaucomadiagnosis #ophthalmology #optometry #medicaleducation #GlaucomaAwarenessMonth

As the new documentary "Below the Belt: The Last Health Taboo" shows, #Endometriosis is much more than a “bad period”. This film that’s free to watch on PBS, spotlights the challenges of living with endometriosis and finding a cure for this disease that is too often disregarded by physicians. In a recent study led by Francois H. Cornelis, MD, PhD, IceCure Medical’s #ProSense #cryoablation technology demonstrated an impressive efficacy rate of 92.8% in avoiding secondary surgeries and Pain-free survival rates of 93.75% at 6 months post-procedure. As advocates for #womenshealth, IceCure is committed to making an impact and raising awareness about this crucial health issue. Read more about this groundbreaking #clinicaltrial here: https://lnkd.in/dUYp2JP7

We recently shared new field data from D. Kyle Hogarth, MD, FCCP UChicago Medicine & Dr. Bobby Mahajan MD, FCCP, DAABIP Medical Director, Interventional Pulmonology Inova Fairfax Hospital detailing early experience using the Galaxy System. The data represents findings from 165 total patient procedures investigating 190 total lesions. Key findings include: * The white papers reported diagnostic yield with a range of 92-96% observed by Dr Hogarth and 96% by Dr Mahajan. * The average lesion size ranged from 14mm to 16mm, with more than one-third of them less than or equal to 10mm in size. * Approximately 88% and 75% of lesions navigated to and biopsied by Dr Hogarth and Dr Mahajan, respectively, were found in the outer 1/3 or pleura of the lung. Overall, the average procedure time did not exceed 46 minutes at either location. Learn more: https://hubs.ly/Q02tkv6-0 #NoahMedical #LungCancer #RoboticBronchoscopy #EarlyDetection #DiagnosticYield #WeListenedWeDelivered

We recently shared new field data from D. Kyle Hogarth, MD, FCCP UChicago Medicine & Dr. Bobby Mahajan MD, FCCP, DAABIP Medical Director, Interventional Pulmonology Inova Fairfax Hospital detailing early experience using the Galaxy System. The data represents findings from 165 total patient procedures investigating 190 total lesions. Key findings include: * The white papers reported diagnostic yield with a range of 92-96% observed by Dr Hogarth and 96% by Dr Mahajan. * The average lesion size ranged from 14mm to 16mm, with more than one-third of them less than or equal to 10mm in size. * Approximately 88% and 75% of lesions navigated to and biopsied by Dr Hogarth and Dr Mahajan, respectively, were found in the outer 1/3 or pleura of the lung. Overall, the average procedure time did not exceed 46 minutes at either location. Learn more: https://hubs.ly/Q02tkv6-0 #NoahMedical #LungCancer #RoboticBronchoscopy #EarlyDetection #DiagnosticYield #WeListenedWeDelivered

"AI can significantly enhance diabetic retinopathy screening by providing faster analysis, scalability to larger populations, and higher accuracy in detecting early signs," shared Dr. Sobha Sivaprasad during last Thursday’s Orbis Cybersight webinar on "Eyes on the Future: Transforming Diabetic Retinopathy Screening Globally through Innovative Technologies." During the hour-long talk, attended by eye care professionals from 87 countries, Dr. Sivaprasad further delved into various diabetic retinopathy screening models, such as hospital-based screening models, community-based screening models, and teleophthalmology screening models, supported by real-world data. Learn more about the impact, success stories, and challenges of these various screening programs presented by accessing the recording of the webinar. #remidio #orbis #cybersight #diabeticretinopathy #artificialintelligence #teleophthalmology #community #publichealth #diabetes

#earlydetectionsaveslives American College of Cardiology recommends that all women have a risk assessment by age 25 to determine if #breastcancer screening earlier than age 40 is needed. They continue to recommend #annualscreening starting at age 40 for #women of average risk, but earlier and more intensive screening for high-risk patients. SonoCiné technology can significantly help with early detection! Head to our website to learn more about our breast screening exams that can detect #breastcancers and book your appointment: thesonocenter.com #BreastExam #BreastScreening #BreastUltrasound #SonoCine #EarlyDetection #EarlyDetectionSavesLives #Mammogram #BreastHealth #BreastCancerAwareness #awbus #DenseBreasts #DenseBreastTissue #BreastHealthAwareness

Did you know, 1 in 100 Americans live with #crohnsdisease or #ulcerativecolitis (#IBD)? Here is how Motilent is making a difference for those with #crohnsandcolitis : 🎯 Bringing #precision to #crohns : GIQuant, continues to provide quantified and objective scores to track treatment response in small bowel Crohn’s disease. Clinically used in both the US & UK redefining patient management. 🌟 Addressing Critical Needs: The James Lind Alliance IBD priority setting list identified perianal Crohn’s disease as a priority 5, we’re committed to advancing this area of medicine starting with vEUA. 🌍 Supporting research internationally: Entrolytics; Motilent’s cloud-based image viewing platform is now ready for clinical use in the US! It is already actively being used in over 300 projects, fostering international collaboration and providing researchers with the tooling they need to conduct pioneering research.  🤝 Supporting many of the biggest IBD Trials: With esteemed groups like International Bowel UltraSound (IBUS) Group, we're proud to support some of the most prominent IBD trials scheduled for 2024. These efforts represent just a glimpse of how we're dedicated to our mission of changing the way we see the gut to support individuals living with Crohn's and Colitis. #gastroenterology #abdominalradiology #medtech #precisionmedicine #IBDVisable #ibdawareness

Unlocking the Potential of FFR-CT in Revascularization Planning. 🔬 Our latest study represents a pioneering investigation into the capability of coronary FFR-CT to predict graft failure post-CABG. 📊 Findings unveiled that elevated FFR-CT values at future anastomosis sites correlated with subsequent graft dysfunction. This innovative approach facilitates more informed decision-making on coronary revascularization strategies, potentially prompting increased consideration of PCI in cases of multivessel disease. 💡 Implications: Our results underscore the importance of functional evaluation and FFR-CT role in guiding revascularization strategies. Notably, surgical guidelines may not mandate pre-revascularization functional assessment, potentially contributing to graft failures. Our study sheds light on FFR-CT's critical role in mitigating such risks. 🔍 To learn more, learn with our cases: https://lnkd.in/gbsBhj27 #Research #CABG #FFRCT #Cardiology #HealthcareInnovation https://lnkd.in/da_nH8jQ

Today, a staggering 26 million women in the US alone suffer from uterine fibroids or myomas, the most common gynecological non-cancerous tumor in premenopausal women. Hysterectomy remains the major therapeutic approach to remove these painful fibroids. As we recognize fibroid awareness month, we are highlighting the unmet need for better solutions to treat uterine fibroids. Ark Surgical Ltd.'s newly FDA-approved #LapBox device enables a minimally invasive option for myomectomies and hysterectomies, empowering women with choice in their healthcare. #FibroidAwarenessMonth #WomensHealth #HealthcareInnovation

✨Don't miss New Horizons in Amyloidosis (NHA) on 28 February 2024, an exciting, free event led by Course Director Dr rodney falk! Register for FREE here 👉 https://ow.ly/WSta50QtTOa The immersive NHA programme is designed to increase knowledge of the evolving diagnosis, treatment and management practices in cardiac amyloidosis. 🔍Increase the awareness of at-risk patients 🔍Improve understanding of screening procedures 🔍Provide guidance on the use of imaging for cardiac amyloidosis diagnosis 🔍Improve awareness of current and emerging treatment 🔍Provide guidance on the management of key comorbidities #Amyloidosis #NHA2024 #Cardiology